Isoflavones regulate innate immunity and inhibit experimental colitis.

Area of Science:

• Immunology
• Gastroenterology
• Nutritional Science

Background:

• Inflammatory bowel diseases (IBD) stem from dysregulated gut immune responses to antigens.
• The role of dietary antigens, like soybean isoflavones, in IBD pathogenesis or prevention remains unclear.
• Soybean isoflavones are abundant, biologically active compounds with potential immunomodulatory effects.

Purpose of the Study:

• To investigate the effects of bioavailable soybean isoflavones on gut immunity.
• To determine if isoflavones protect against tissue damage in a mouse model of colitis.
• To assess the impact of isoflavones on immune cell function in the gut.

Main Methods:

• Mice were administered daidzein-rich isoflavone aglycones (DRIA) for one week.
• Colitis was induced using 2% dextran sodium sulfate (DSS) in drinking water for four days.
• Effects were assessed via colon histopathology, body weight changes, and mesenteric lymph node (MLN) cell analysis.

Main Results:

• DRIA dose-dependently inhibited interleukin (IL)-6 and IL-8 production in stimulated monocytes.
• Mice treated with DRIA exhibited reduced colon inflammation and tissue damage compared to controls.
• DRIA administration led to decreased interferon-gamma, IL-6, and IL-12p40, and increased IL-10 secretion, alongside reduced antigen-presenting cell (APC) activation in MLNs.

Conclusions:

• Ingested DRIA effectively downregulates antigen-presenting cell (APC) functions.
• DRIA demonstrates a protective effect against dextran sodium sulfate (DSS)-induced colitis.
• Soybean isoflavones represent a potential dietary strategy for managing gut inflammation and IBD.